ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Company Overview - ProMIS Neurosciences, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) [3] - The company utilizes a proprietary target discovery engine, ProMIS™, which employs a thermodynamic, computational discovery platform to identify Disease Specific Epitopes on misfolded proteins [3] Product Development - The lead product candidate, PMN310, is a humanized monoclonal antibody designed to selectively bind toxic Aβ oligomers, which are implicated in the progression of Alzheimer's disease, while avoiding binding to plaque or monomers [3] - PMN310 has successfully completed a Phase 1a clinical study and is currently in a Phase 1b clinical trial involving Alzheimer's disease patients [3] Upcoming Events - Neil Warma, the CEO of ProMIS Neurosciences, will participate in a fireside chat at the 37th Annual Roth Conference on March 18, 2025, at 8:00 a.m. PT in Dana Point, CA [1] - A live webcast of the event will be available on the company's website for at least 30 days following the event [2]